Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Haematologica|March 23, 2023
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Guillaume Richard-Carpentier, Caitlin R Rausch, Koji Sasaki, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesVera Adema, Irene Ganan-Gomez, Feiyang Ma, et al.
British Journal of Haematology|August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
British Journal of Haematology|December 9, 2024
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesisTamanna Haque, Aditi Shastri, Pinkal Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxAlexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Pageof 5